AU3791699A - Naphtho{2,3-b}heteroar-4-yl derivatives - Google Patents

Naphtho{2,3-b}heteroar-4-yl derivatives

Info

Publication number
AU3791699A
AU3791699A AU37916/99A AU3791699A AU3791699A AU 3791699 A AU3791699 A AU 3791699A AU 37916/99 A AU37916/99 A AU 37916/99A AU 3791699 A AU3791699 A AU 3791699A AU 3791699 A AU3791699 A AU 3791699A
Authority
AU
Australia
Prior art keywords
heteroar
naphtho
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37916/99A
Inventor
Arlene Joan Dietrich
Paul Jeffrey Dollings
Jay Edward Wrobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU3791699A publication Critical patent/AU3791699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU37916/99A 1998-05-12 1999-05-10 Naphtho{2,3-b}heteroar-4-yl derivatives Abandoned AU3791699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7644698A 1998-05-12 1998-05-12
US09076446 1998-05-12
PCT/US1999/010210 WO1999058522A1 (en) 1998-05-12 1999-05-10 Naphtho[2,3-b]heteroar-4-yl derivatives

Publications (1)

Publication Number Publication Date
AU3791699A true AU3791699A (en) 1999-11-29

Family

ID=22132072

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37916/99A Abandoned AU3791699A (en) 1998-05-12 1999-05-10 Naphtho{2,3-b}heteroar-4-yl derivatives

Country Status (8)

Country Link
EP (1) EP1077968A1 (en)
JP (1) JP2002514639A (en)
CN (1) CN1308625A (en)
AR (1) AR019842A1 (en)
AU (1) AU3791699A (en)
CA (1) CA2330555A1 (en)
TW (1) TW446704B (en)
WO (1) WO1999058522A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248604B2 (en) 2000-01-21 2012-02-29 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
CN100334088C (en) * 2003-05-15 2007-08-29 霍夫曼-拉罗奇有限公司 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN102935081B (en) 2005-09-14 2015-03-04 武田药品工业株式会社 Dipeptidyl peptidase inhibitors for treating diabetis
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PT2531501E (en) 2010-02-03 2014-02-17 Takeda Pharmaceutical Apoptosis signal-regulating kinase 1 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6423372B2 (en) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN106749169B (en) * 2016-11-07 2020-04-21 浙江工业大学 Chiral preparation method of Ertiprotafib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506348A (en) * 1993-06-14 1996-07-09 ファイザー・インク． Secondary amines as antidiabetic and antiobesity agents
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
CA2227691A1 (en) * 1995-08-28 1997-03-06 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents

Also Published As

Publication number Publication date
WO1999058522A1 (en) 1999-11-18
CN1308625A (en) 2001-08-15
TW446704B (en) 2001-07-21
CA2330555A1 (en) 1999-11-18
AR019842A1 (en) 2002-03-20
JP2002514639A (en) 2002-05-21
EP1077968A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
AU3791699A (en) Naphtho{2,3-b}heteroar-4-yl derivatives
PT1589017E (en) 12,13-modified epothilone derivatives
AU4006800A (en) 1,2-dithiolane derivatives
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU6018799A (en) Fused-benzene derivatives useful as herbicides
AU5235699A (en) Sulfonamide derivatives
HU9901911D0 (en) Diaza-spiro[3,5]nanone derivatives
AU1379900A (en) Novel substituted phenyloxazolidone derivatives
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
AU3167699A (en) Vitamin d derivatives substituted at the 2beta-position
AU4435199A (en) Isoflavone derivatives
AU6228299A (en) 2-substituted-d-homooxasteroid derivatives
AU2002218400A1 (en) 3-substituted 2,7-naphthyridin-1-yl derivatives
AU2924299A (en) Condensed 4-thioxopyrimidine derivatives as microbicides
AU7449998A (en) 2,3-dihydrobenzofuran derivatives
AU3534499A (en) Radicicol derivatives
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
AU5233699A (en) Sulfonamide derivatives
AU2640999A (en) 1-azaindolizine derivatives
AU4141099A (en) Pyrazolyldioxothiochromanoyl derivatives
AU2894099A (en) Phenanthrofuran derivatives
AU5239899A (en) Amidophosphate derivatives
AU2641099A (en) Imidazoquinazoline derivatives
AU2641299A (en) Benzofuran derivatives
AU2049601A (en) Benzofuran derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase